Sign in to fuzzto save your conversations, follow your research and come back anytime.
Emcure Pharmaceuticals
SectorHealthcare
Emcure Pharmaceuticals Limited is an Indian pharmaceutical company founded in 1981. It develops, manufactures, and globally markets pharmaceutical products across various therapeutic areas. The company operates 13 manufacturing facilities in India and has a presence in over 70 countries, with a strong focus on India, Europe, and Canada. Emcure specializes in orals, injectables, and biotherapeutics, covering areas such as gynecology, cardiovascular, vitamins, minerals, nutrients, HIV antivirals, blood-related, and oncology treatments. The company has a portfolio of differentiated products, including chiral molecules, complex APIs, biologics, and novel drug delivery systems. Emcure has commercialized six in-house manufactured biologics and holds patents for specific treatments. The company expanded through mergers, acquisitions, and establishment of new facilities over the years. In July 2024, Emcure launched an Initial Public Offer.
In the news
Emcure Pharma shares rise 3% on subsidiary merger approval
CDSCO waives trials for lenacapavir, boosting India's HIV drug access
FTSE Rebalancing: What It Means for India's New Market Entrants
Nifty shows pullback signs after 6% decline, technical correction may end
ICICI Securities rates Emcure Pharma as Buy with ₹2,305 target
Emcure Pharma gains 3% on USFDA EIR; stock up 2.34% on strong Q1
Motilal Oswal Sets Emcure Pharma Target at ₹2260; Shares Rise 3%
Emcure Pharma shares up 3% after CDSCO approves semaglutide for MASH
Sensex, Nifty extend gains: Raymond defence CEO appointment boosts stock
MarketSmith India Recommends Emcure, Apollo Micro for July 3
Bain Capital's Masterclass: From Emcure Exit to New Frontiers
Bain Capital completes full exit from Emcure Pharma for ₹350 crore
Emcure Pharma shares surge 4% after Bain Capital divests ₹612 cr stake
Market Experts Share Stock Picks: Buy, Sell or Hold Ratings
6 Short-term Stock Picks: Coal India, Torrent Pharma & More
Emcure Q4 profit jumps 24% to ₹243.74 crore on strong international growth
Emcure Pharma shares fall 6% post Q4 results despite 24% profit jump
Emcure Pharma Q4 Results: 29% profit growth, stock falls 5%
Mauritius Entity Sells ₹289 Cr Emcure Shares to Norges Bank
Emcure cuts Poviztra semaglutide drug price by 55% post patent expiry
Company insights, generated from the most recent coverage.
Trading ~8.8% below the 52-week high of ₹2,100.70 after a 43% one-year and 23.8% six-month run — the stock is in a natural profit-booking zone.
Down 1.08% at ₹1,916 on Oct 6 with volume 92% below the 1-month average — a thin, low-conviction drift, not institutional selling.
Flat-to-negative over 1 week (-0.60%) and 1 month (-0.59%) against +4.19% over 3 months — consolidation after a strong run, not a trend break.